INSPECS Group plc (INPEF) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of INSPECS Group plc $0.12, price $1.08, upside -88.9%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value $0.1200 · Strongly overvalued (−89%)
!Quality 46/100
!Weak Growth(revenue 3y −1.6 %/yr)
!Loss-making · -5.0% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers(3/11)
!Narrow moat14/100
!Insider activity45/100
!Evidence only low, so the estimate is less certain
Watch INSPECS Group plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
INSPECS Group plc designs, produces, sells, markets, and distributes fashion eyewear, lenses, and OEM products in the United Kingdom, Europe, North America, South America, Asia, Africa, and Australia. It operates through Frames and Optics product distribution and Manufacturing segments.
Show more
INSPECS Group plc designs, produces, sells, markets, and distributes fashion eyewear, lenses, and OEM products in the United Kingdom, Europe, North America, South America, Asia, Africa, and Australia. It operates through Frames and Optics product distribution and Manufacturing segments. The company offers its products under the retail brands, such as Barbour, Barbour International, BUFFALO David Bitton, CAT, Free Country, Henri-Lloyd, Hype, JOSEPH, Lamb, Liberty, Lyle & Scott, Marc O'Polo, MINI, O'Neill, RADLEY, Superdry & Co, TALBOT RUNHOF, Ted Baker, and VIKTOR & ROLF and in house brands under BOTANIQ, SAVILE ROW Titanium, SAVILE ROW, BRENDEL Eyewear, FREIGEIST, HUMPHREY'S eyewear, JOS ESCHENBACH, and TITANFLEX names. INSPECS Group plc was founded in 1988 and is based in Bath, United Kingdom.
Stock analysis
INSPECS Group plc (INPEF) currently trades at $1.08, while our model-based Fair Value estimate is $0.1200, implying the stock looks roughly 800.1% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $0.7500 per share, and 1 of the 6 models we run sit above the $1.08 price.
Bear case: the Earnings-Based group reads lowest at $0.1400, and 5 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0900 (bear) to $0.1500 (bull), the price of $1.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
INSPECS Group plc reported revenue of £192M in FY2025 versus £183M in FY2021, a compound +1.2%/yr. Reported net income was −£9.6M in FY2025.
Key figures
Market cap $110M · P/S ratio 0.62 · EPS (TTM) $−0.0400 · Net margin −5.0% · Return on equity −3.8% · Return on assets (EBIT) 1.4% · Operating margin 3.1% · Revenue (TTM) $192M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades near its 52-week high, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −89%, INPEF screens richer than that median.
Fair Value models
Bear $0.0900Fair Value $0.1200Bull $0.1500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.1/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.6% (2021) → 3.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Bottom 25%
Fair Value upside−89% · Bottom 25%
Profitability
Return on assets2% · Below median
Net margin (TTM)−5% · Bottom 25%
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth1% · Below median
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B1.38× · Cheaper than median
P/S (TTM)0.57× · Cheapest 25%
EV/EBITDA9.9× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)7· sector 28
PAST (return on equity)0· sector 25
HEALTH (low debt)77· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "INSPECS Group plc Fair Value". https://www.fairvalue-calculator.com/stock/INPEF
Frequently asked questions
Is INSPECS Group plc (INPEF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1200 versus a price of $1.08, about −89% upside (overvalued).
What is the fair value of INPEF?
Our model-based fair value for INSPECS Group plc is $0.1200 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.08.
What is the quality score of INPEF?
INSPECS Group plc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for INSPECS Group plc (INPEF)?
Our model-based price target is the fair value of $0.1200 (as of Sep 24, 2026) from 6 valuation models. Cautious scenario $0.0900, optimistic scenario $0.1500. It is a calculation from audited fundamentals, not an analyst target.
What is the INSPECS Group plc stock forecast for 2026?
Our models put fair value at $0.1200, about −89% upside versus a price of $1.08 (overvalued). Cautious scenario $0.0900, optimistic scenario $0.1500. The calculation is refreshed regularly with new filings.
What is the revenue of INSPECS Group plc (INPEF)?
INSPECS Group plc reported trailing-twelve-month revenue of about $192M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of INSPECS Group plc (INPEF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For INSPECS Group plc it is $0.1200 per share (as of Sep 24, 2026), against a price of $1.08. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is INSPECS Group plc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, INPEF trades above its calculated fair value: price $1.08, fair value $0.1200, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INPEF?
No. The price is what the market pays today ($1.08); the fair value is what the company's own numbers justify ($0.1200). For INSPECS Group plc the two are $0.9600 per share apart. That gap is exactly why we show both numbers side by side.
How much is INSPECS Group plc worth?
The market values INSPECS Group plc at about $110M (market capitalisation, as of Sep 24, 2026). Per share that is $1.08; our models calculate a fair value of $0.1200 per share.
What do the bullish and bearish scenarios say about INPEF?
Our models span a range for INSPECS Group plc: cautious scenario $0.0900, base $0.1200, optimistic $0.1500 per share (as of Sep 24, 2026, price $1.08). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of INSPECS Group plc (INPEF)?
Balance-sheet figures for INSPECS Group plc (as of Sep 24, 2026): return on equity −3.8%, debt of 0.46 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is INPEF from its 52-week high?
INSPECS Group plc trades at $1.08, about 0% below its 52-week high of $1.08 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1200 is for.
Which stocks are comparable to INSPECS Group plc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is INSPECS Group plc stock attractive at the current price?
The data as of Sep 24, 2026: price $1.08, calculated fair value $0.1200 (−89%), Quality Score 46/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INPEF calculated?
We run INSPECS Group plc through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. INSPECS Group plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of INSPECS Group plc (INPEF)?
The closing price on Sep 18, 2026 was $1.08. Our model-based fair value is $0.1200, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with INSPECS Group plc right now?
The price sits above even our optimistic bull case ($0.1500). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of INSPECS Group plc
How large is the market capitalisation of INSPECS Group plc (INPEF)?
The market capitalisation of INSPECS Group plc is $110M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of INSPECS Group plc (INPEF)?
The price-to-sales ratio of INSPECS Group plc is 0.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of INSPECS Group plc (INPEF)?
Earnings per share at INSPECS Group plc are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of INSPECS Group plc (INPEF)?
The net margin of INSPECS Group plc is −5.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of INSPECS Group plc (INPEF)?
The return on equity (ROE) of INSPECS Group plc is −3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of INSPECS Group plc (INPEF)?
On an EBIT basis the return on assets of INSPECS Group plc is 1.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of INSPECS Group plc (INPEF)?
The operating margin of INSPECS Group plc is 3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at INSPECS Group plc (INPEF)?
Revenue at INSPECS Group plc is growing +1.4% versus a year earlier (3y avg −1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does INSPECS Group plc (INPEF) generate?
The free cash flow of INSPECS Group plc is −$2.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does INSPECS Group plc (INPEF) carry?
The net debt of INSPECS Group plc is $32.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch INSPECS Group plc in the live analysis
One click puts INSPECS Group plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026